Biogen Inc. (BIIB) soared higher Wednesday as traders and investors buy in anticipation of the FDA's meeting on the company's Alzheimer's med aducanumab. BIIB is up around $110 per share or around 44%. Let's check out the charts and indicators of BIIB to see if this rally can carry on further.
More from Investing
The Fed backs off on claims that inflation is transitory and sets the stage for future rate hikes.
Here are stocks that should benefit from the desire of more consumers for beauty products and natural products.
The new high in the OBV line could be foreshadowing all-time highs for SHOP.